Floatz logo

Fremanezumab

Headache Disorders

University of Aarhusmonoclonal_antibodyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Headache Disorders cohort.

Asset / SponsorPhaseRating
Spn-538
Supernus Pharmaceuticals, Inc.
Phase 4B
Idebenone
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3B
Bimatoprost
Manistee Partners
Phase 2CCC
Xeomin®
Norwegian University of Science and Technology
Phase 1/2CCC
Glucagon
Norwegian University of Science and Technology
Phase 1/2CC

View all 13 →

Same molecule, other indications

Fremanezumab is also rated in:

migraine disorderDormant
BBB
Indicative ·
74 / 100
View asset →
migraine disorderDormant
BB
Indicative ·
65 / 100
View asset →
sleep disorderDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →